Related Experiment Video
Updated: Jul 4, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Prodrugs in cardiovascular therapy.
Marinella G Sandros1, Chady B Sarraf, Maryam Tabrizian
1Department of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, Canada H3A2B4.
Molecules (Basel, Switzerland)
|June 19, 2008
Summary
Prodrugs offer solutions for cardiovascular drug limitations like toxicity and poor solubility. This review explores advanced prodrug strategies and delivery systems for improved cardiovascular disease treatment with fewer side effects.
Area of Science:
- Pharmacology
- Drug Delivery
- Medicinal Chemistry
Background:
- Cardiovascular drugs often face challenges including first-pass metabolism, leading to inactivation and toxic byproducts.
- Prodrugs are inactive drug derivatives designed to overcome limitations of parent drugs such as toxicity, instability, poor solubility, and lack of targeting.
- Cardiovascular medications are prime candidates for prodrug development due to these inherent issues.
Purpose of the Study:
- To review the latest advancements in prodrug development for treating cardiovascular diseases.
- To examine the integration of prodrug strategies with novel drug delivery systems.
- To highlight improvements in target specificity and controlled drug release for cardiovascular therapies.
Main Methods:
- Literature review of recent scientific publications on prodrugs and cardiovascular diseases.
- Analysis of prodrug design principles and their application to cardiovascular drug challenges.
- Exploration of drug delivery methodologies combined with prodrug approaches.
Main Results:
- Prodrugs effectively address issues like poor solubility and first-pass metabolism in cardiovascular drugs.
- Combined prodrug and advanced delivery systems enhance target specificity and controlled release.
- Emerging prodrug strategies show promise for reducing side effects and improving therapeutic outcomes.
Conclusions:
- Prodrugs represent a significant advancement in managing cardiovascular diseases.
- The synergy between prodrug design and drug delivery systems offers a powerful platform for next-generation cardiovascular therapeutics.
- Further research into these combined approaches is warranted to optimize patient treatment and minimize adverse events.
Related Concept Videos
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...